Pfizer: CMA wrongly excluded comparators in excessive pricing decision
Pfizer has urged the UK’s Competition Appeal Tribunal to overturn the national enforcer’s finding that it excessively priced a lifesaving anti-epilepsy medication, arguing the authority erred in law by refusing to assess comparative products.
To read more
Subscribe to Global Competition Review
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.